HealthEquity (HQY)
(Delayed Data from NSDQ)
$98.82 USD
+1.62 (1.67%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $98.64 -0.18 (-0.18%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$98.82 USD
+1.62 (1.67%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $98.64 -0.18 (-0.18%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
Zacks News
Here's Why You Should Hold on to IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Robust domestic and international performances by the CAG arm are driving IDEXX's (IDXX) fourth-quarter top line.
Tandem Diabetes (TNDM) to Offer Insulin Delivery With Smartphone
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:connect is the first-ever app on both iOS and Android operating systems to receive FDA clearance for insulin delivery from a personal smartphone.
OPKO's (OPK) NGENLA to Offer GHD Treatment in European Union
by Zacks Equity Research
OPKO's (OPK) marketing authorization for NGENLA in the European Union stands to benefit children and adolescents affected by growth hormone deficiency.
Here's Why You Should Hold on to Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) better-than-expected fourth-quarter results and impressive COVID-19 response-related revenues.
HealthEquity (HQY) Up 10.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for December 21st
by Zacks Equity Research
BLBD, CBRL, HQY, LE and PHX have been added to the Zacks Rank #5 (Strong Sell) List on December 21, 2021.
New Strong Sell Stocks for December 10th
by Zacks Equity Research
AVAV, HQY, MESA, SWK, and CGNX have been added to the Zacks Rank #5 (Strong Sell) List on December 10, 2021.
Here's Why You Should Hold on to Align Technology (ALGN) Now
by Zacks Equity Research
Investors are optimistic about Align Technology's (ALGN) better-than-expected results and growing uptake of iTero scanners in the third quarter of fiscal 2021.
Medtronic (MDT) Gets Health Canada License for Hugo RAS System
by Zacks Equity Research
The receipt of the Health Canada license for Medtronic's (MDT) Hugo RAS System is likely to enhance accessibility to robotic-assisted surgery in Canada.
HealthEquity (HQY) Q3 Earnings Beat, FY 2022 View Lowered
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs besides recording robust Interchange revenues in the third quarter of fiscal 2022.
Why Seasoned Investors are Retaining Select Medical (SEM) Stock
by Zacks Equity Research
Select Medical (SEM) is focused on making strategic acquisitions to boost its business through inorganic growth.
Acadia (ACHC) & Orlando Health Form JV, Boosts Presence
by Zacks Equity Research
Acadia Healthcare Company (ACHC) expects to take on Orlando Health South Seminole Hospital's management responsibilities of the behavioral health program.
Earnings Preview: HealthEquity (HQY) Q3 Earnings Expected to Decline
by Zacks Equity Research
HealthEquity (HQY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After Plunging 13.3% in 4 Weeks, Here's Why the Trend Might Reverse for HealthEquity (HQY)
by Zacks Equity Research
HealthEquity (HQY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
PINC or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PINC vs. HQY: Which Stock Is the Better Value Option?
PINC vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PINC vs. HQY: Which Stock Is the Better Value Option?
HealthEquity (HQY) Down 1.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Company News for Sep 10, 2021
by Zacks Equity Research
Companies In The News Are: LULU, RH, HQY, MRNA
HealthEquity (HQY) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs and records robust Interchange revenues in the second quarter of fiscal 2022.
HealthEquity (HQY) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 11.11% and 2.12%, respectively, for the quarter ended July 2021. Do the numbers hold clues to what lies ahead for the stock?
AMN Healthcare (AMN) Hits 52-Week High: What's Behind It?
by Zacks Equity Research
Investors are optimistic about AMN Healthcare's (AMN) broad array of services.
Zacks Industry Outlook Highlights: HealthEquity, Progyny, Surgery Partners, ModivCare and Agiliti
by Zacks Equity Research
Zacks Industry Outlook Highlights: HealthEquity, Progyny, Surgery Partners, ModivCare and Agiliti
Analysts Estimate HealthEquity (HQY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
HealthEquity (HQY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Medical Services Stocks Countering Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. HQY, PGNY, SGRY, MODV, and AGTI are set to gain the most. However, falling healthcare spending may disrupt the trend.
PINC or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PINC vs. HQY: Which Stock Is the Better Value Option?